AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$KURA

FORD KATHLEEN sold $112K of KURA

FORD KATHLEEN (Chief Operating Officer) sold 10,574 shares of Kura Oncology, Inc. (KURA) at an average of $10.59 ($10.50–$10.75, $0.11M total) across 2 trades over 2026-09-28 to 2026-09-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FORD KATHLEEN
Published Sep 29, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 10:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KURA
Bearish
medium confidence
Mentioned
$KURA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURABearishLow
01

Why it matters

Provides fresh data on insider holdings, useful for short‑term sentiment.

02

Market read

Small insider sell, low materiality, limited trading relevance.

03

What to watch

Potential upcoming clinical milestones may offset sell pressure.

Relevance 3/10Novelty 3/10Timing: post-market today

Background

Form 4 filing discloses insider transactions under a 10b5-1 plan.

Company-level read

Ticker impact

$KURABearishMedium confidence
Context

Chief Operating Officer sold 10,574 shares for $111,931, reducing holdings to 142,986 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Sale size is small relative to market cap, but insider status adds relevance.

Market effects

Sector

Minimal impact on biotech sector; typical insider activity.

Regional

No broader regional effect.

Global

Limited to Kura Oncology investors.

Counterpoint

What could challenge this read

The sale could be routine liquidity management, not a negative signal.

Key entities

  • company
    Kura Oncology, Inc.

    Biotech firm developing oncology therapies.

  • person
    Ford Kathleen

    Chief Operating Officer of Kura Oncology.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KURA insider trading history →

Related articles

OCT 13
$KURAMedAI 8/10

Some rats regained normal blood sugar for a month after an experimental diabetes treatment stopped

Caspian Therapeutics and Kura Oncology (KURA) will discuss the development strategy for KO-7246, an oral menin inhibitor for diabetes, in a webcast. Preclinical findings showed improved glucose control and beta cell expansion in animal models. Caspian plans to conduct a Phase 1 clinical trial to assess safety and insulin production. Kura owns half of Caspian and retains research collaboration rights.

stocktitan.net2 min
SEP 29
$KURAMedAI 8/10

Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes

Caspian Therapeutics and Kura Oncology presented preclinical data on KO-7246, a menin inhibitor, showing potential for diabetes treatment. KO-7246 regenerated β-cell mass and controlled glycemic levels in Type 1 and Type 2 diabetes models. Caspian aims to develop KO-7246 as a best-in-class therapy, with an investor event scheduled for October 13, 2026.

finance.yahoo.com3 min
SEP 9
$KURAMed

KURA Oncology Launches Caspian Therapeutics, Shifting Focus Whil

Kura Oncology (KURA) launched Caspian Therapeutics, a spin-off focused on menin inhibition therapies for diabetes and cardiometabolic diseases. Kura retains 50% ownership. The company's P/S ratio is 14.3x, above its historical median of 10.6x, reflecting growth expectations despite unprofitability. Insider activity shows net selling, while guru investors have mixed positions.

gurufocus.com2 min